Access Pharma Inks Manufacturing, Development Deal With Jiangsu Aosaikang For ProLindac
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Jiangsu Aosaikang Pharmaceutical inked an agreement with Dallas-based Access Pharm to manufacture, develop and commercialize Access's proprietary product ProLindac for the Greater China Region of Mainland China, Hong Kong, Macao and Taiwan, Access announced June 4